People make the best decisions when armed with comprehensible information.
Helping people understanding their health data.
Medicus AI empowers patients to make better decisions by explaining their medical
reports and health data to them in a personalized, easy-to-understand, and visual way.
People make the best decisions when armed with comprehensible information.
Feel great and stay safe in your pregnancy.
Keleya GmbH offers a digital companion during pregnancy that provides important support
and more security to pregnant women. In addition, health insurance companies are able to
identify issues and offer targeted health services which adds further value to future
mothers.
When evidence speaks, the world listens: Generating data that matters.
The real-world evidence platform for drug effectiveness and safety.
XO Life stands for a state-of-the-art communication infrastructure enabling
multidirectional drug-related information exchange between patients, medical experts and
pharma to improve drug effectiveness and safety in the real-world setting.
Treating the cause and not the consequence – a paradigm shift for the healthcare
ecosystem.
ATreg – Giving patients a definitive cure.
With ATreg, ActiTrexx's mission is to offer a one-time treatment based on
specially-activated regulatory T-cells, with the aim to prevent or reduce inflammatory
reactions in conditions like GvHD, solid organ transplantation and autoimmune diseases.
With robust pre-clinical findings, ActiTrexx is preparing for the first human clinical
study.
User-centric biomarker testing for everyone, everywhere.
Truly accessible fluid analysis for tomorrow's diagnostics.
anvajo changes the market for laboratory testing in a disruptive way by offering a
high-quality portable device and entire analytical solution for screening and
monitoring diseases, e.g. CKD. The benefits are immediate and provide accurate test
results at economical costs, accessible for everyone everywhere.
Precision medicine brings the right treatment for everyone, everywhere.
Excellence in liquid biopsy analysis.
With a new minimally invasive blood test, mir|detect
offers a technology with high sensitivity and specificity that allows for the early
detection of testicular germ cell tumors. This test has the potential to reduce
diagnostic operations, adjuvant chemotherapies, redundant cycles of chemotherapy and CT
examinations. Therefore, over- and undertreatment or incorrect treatments can be avoided
and radiation is reduced improving quality of life for patients.
